Neurology, neuropsychiatry, Psychosomatics最新文献

{"title":"Cortisol as a cerebral cortex neurons apoptosis regulator in acute phase of ischemic stroke (clinical and pathological study)","authors":"S. P. Sergeeva, A. A. Savin, P. Litvitsky, L. Gorbacheva, A. Lyundup, I. D. Breslavich, L. A. Savin","doi":"10.14412/2074-2711-2024-1-49-56","DOIUrl":"https://doi.org/10.14412/2074-2711-2024-1-49-56","url":null,"abstract":"In response to ischemic stroke (IS) a natural activation of the stress-realizing system occurs. The features of this activation influence the outcome of the acute period and the prognosis of recovery and can be adjusted. At the same time, the role of the stress-realizing system in the pathogenesis of IS is still unexplored.Objective: to investigate the effect of peripheral blood cortisol concentration on the regulation of apoptosis of neurons of the cerebral cortex in the acute phase of IS.Material and methods. A prospective clinical and pathological study was performed. It included 9 patients with IS in the left middle cerebral artery territory who were admitted to hospital and died in the hyperacute phase of IS and had no infectious complications, allergic reactions or oncological diseases and who did not undergo thrombolysis. The cerebral cortex was examined. Neuron-specific enolase (NSE), protein 53 (p53), caspase 3, caspase 8, Fas receptor (CD95), and Fas apoptotic inhibitory molecule 2 (FAIM2) were determined on the slices using an indirect immunoperoxidase immunohistochemical staining method. A total of 567 microscopic fields were analysed for the group of patients with IS and 63 fields for the control group (three people). Before death, the blood concentrations of sFas, sFasL, cortisol, adrenocorticotropic hormone, adrenaline and norepinephrine were determined by enzyme immunoassay (the control group consisted of 28 people).Results. Significant correlation was found between the proportion of casp3-positive neurons and the concentration of cortisol in peripheral blood in zones 2 (r=0.263; p<0.01) and 3 (r=0.383; p<0.01). In the 2nd zone, significant negative correlation was found with the concentrations of sFas (r=-0.177; p<0.05) and sFasL (r=-0.164; p<0.05); in the 3rd zone, significant positive correlation was found with the ratio of the concentrations of sFasL and sFas (r=0.240; p<0.01). The proportion of Fas-positive neurons in the cerebral cortex correlated significantly with the concentration of the soluble form of this molecule (for the 1st zone – r=0.222, for the 2nd zone – r=0.438, for the 3rd zone – r=0.289; p<0.01) and the ratio of the concentrations of sFasL and sFas (respectively: r=0.231, r=0.266 and r=0.281; p<0.01) in the peripheral blood.Conclusion. Peripheral blood cortisol concentration is a factor that determines the regulation of apoptosis of neurons in the cerebral cortex in the acute phase of IS.","PeriodicalId":19252,"journal":{"name":"Neurology, neuropsychiatry, Psychosomatics","volume":"72 3","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-02-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140448351","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Psychometric Properties of the Draw a Story (DAS) Test in Depressed and Normal Children","authors":"R. Ashtari, F. Khormaei, C. Rahimi, N. Mohammadi","doi":"10.14412/2074-2711-2024-1-33-36","DOIUrl":"https://doi.org/10.14412/2074-2711-2024-1-33-36","url":null,"abstract":"Objective: understanding the problems of depressed children is important, as they may express their issues through painting and storytelling, which can provide insight into their excitability and self-image. This study investigated the psychometric properties of the Draw a Story test in children with depression and normal ones.Material and methods. The participants of this study included 60 fourth and fifth grade students in Yazd province, who were divided into two groups; depressed and normal. Then, each group was evaluated by drawing a story test (DAS).Results. The results showed that there was a significant difference between the depressed and normal groups in terms of self-image and emotion content, as determined by a two-way analysis of variance. The normal group significantly demonstrated a stronger self-image and emotional state than the depressed group. There was no significant difference between boys and girls in terms of self-image. However, there was a significant difference in their emotional expression, with girls being more adept at expressing their emotions compared to boys. Convergent validity of the DAS was established by correlating it with the DSRS test for self-image and emotion, resulting in correlations of -0.67 and -0.74, respectively. The reliability of the DAS test was assessed using the test-retest method for self-image and emotion, yielding coefficients of 0.82, 0.90, respectively. Additionally, the raters' agreement coefficient was calculated for self-image and emotion, and was 0.68 and 0.82, respectively.Conclusions. The results of this study revealed the reliability and validity of the test (DAS) in the group of depressed and normal children. This test can be used to diagnose children with depression.","PeriodicalId":19252,"journal":{"name":"Neurology, neuropsychiatry, Psychosomatics","volume":"16 20","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-02-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140450515","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Sleep and stress at work and in the family among young people","authors":"V. Gafarov, E. Gromova, I. Gagulin, D. Panov, A. N. Tripelgorn, A. Gafarova","doi":"10.14412/2074-2711-2024-1-37-41","DOIUrl":"https://doi.org/10.14412/2074-2711-2024-1-37-41","url":null,"abstract":"Objective: to investigate the relationship between the quality and duration of sleep and stress at work and at home in people aged 25–44 years living in Novosibirsk.Material and methods. The study of a representative cohort of people aged 25–44 years was conducted in 2013–2016 in one of the districts of Novosibirsk (budget topic No. AAAA-A17-117112850280-2). A total of 975 individuals were examined (427 men, mean age – 34±0.4 years, response rate – 71%; 548 women, mean age – 35±0.4 years, response rate – 72%). The general examination was conducted according to the standard methods of the WHO program “MONICA-psychosocial (MOPSY)”. The standard Jenkins questionnaire was used to assess the quality and duration of sleep. Scales to assess stress at home (scale “Knowledge and attitude towards one’s own health”) and at work (Karazek scale) were included in the standard questionnaire.Results. Men aged 25 to 44 with sleep disorders were more likely to report that they “dislike their work” (52.2%) and that their attitude towards work is “average” (50.7%). It is rare for both men (46.8%) and women (56.6%) to relax and have rest after a normal working day. Women with sleep problems (56.5 %) stated that they are unable to rest adequately at home. Both men and women with sleep disorders confirmed that there had been serious conflicts in the family in the last 12 months: “several” times\" (57.1 % and 55.8 % respectively) or “often” (53.3 % and 68.4 % respectively). Women with a sleep duration of 5–6 hours stated that they “never” (36.4 %) or “rarely” (36.8 %) manage to relax and recover after a regular working day; for 33.3 %, responsibilities at work have “increased”; 37.2 % have started to do extra work.Conclusion. A correlation was found between sleep disturbances and their duration and stress both at work and at home.","PeriodicalId":19252,"journal":{"name":"Neurology, neuropsychiatry, Psychosomatics","volume":"263 ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-02-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140450835","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Treatment of cognitive impairment in patients with cerebral infarction in the internal carotid arteries circulation system: results of a multicentre, randomized, double-blind, placebo-controlled clinical trial","authors":"D. Khasanova, A. Yakupova, P. Kamchatnov, Z. Chefranova, E. I. Bogdanov, P. Pilipenko, N. Khasanova","doi":"10.14412/2074-2711-2024-1-24-32","DOIUrl":"https://doi.org/10.14412/2074-2711-2024-1-24-32","url":null,"abstract":"Objective: to evaluate the efficacy and safety of the Prospecta drug in the treatment of cognitive impairment (CI) in patients with ischemic stroke (IS) in the carotid vascular territory.Material and methods. The double-blind, placebo-controlled, randomized clinical trial enrolled 246 patients aged 40 to 75 years with IS in the carotid vascular territory within 72 hours of stroke onset, moderate CI (<26 points on the Montreal Cognitive Assessment, MoCA), full consciousness (15 points on the Glasgow Coma Scale), moderate severity of stroke (8–12 points on the National Institute of Health Stroke Scale, NIHSS), moderate impairment of activity (2–3 points on the – Modified Rankin Scale, mRs). At visit 1, complaints and medical history were collected, vital signs (VS) and laboratory parameters were recorded, CI was assessed according to MoCA and the Glasgow Coma Scale, NIHSS and mRs were filled out. Patients were randomized into two groups: in the first group they received Prospecta for 90 days, in the second group placebo (PL) following a similar regimen. The groups were comparable in terms of demographic and baseline clinical characteristics. After 90 days, complaints, medical history, VS, laboratory parameters and assessment of CI according to MoCA were recorded, and NIHSS and mRs questionnaires were filled out again. The intention-to-treat (ITT) efficacy analysis was performed based on the results of the treatment and follow-up of the Full analysis set (FAS), which comprised 241 patients (122 patients in the Prospecta group and 119 patients in the PL group; 4 patients were excluded from the ITT analysis because they were erroneously included in the study). The results of the per-protocol (PP) analysis are shown in square brackets.Results. The 90-day use of Prospecta reduced the severity of CI in patients with carotid IS compared with placebo therapy. MoCA scale scores increased from 20.7±3.5 [20.9±3.0] to 24.6±2.9 [25.2±2.5] points in the Prospecta group and from 21.7±2.4 [21.6±2.4] to 24.5±3.0 [24.8±2.8] points in the PL group (p=0.0006 [p=0.0014]). 42 adverse events (AEs) were recorded in 32 (26.0%) patients in the Prospecta group and 37 AEs in 28 (23.0%) patients in the PL group (p=0.656). All AEs in the Prospecta group were not significantly related to the use of the drug. No deaths or recurrent IS were recorded.Conclusion. Prospecta is an effective and safe treatment for CI in patients with carotid IS","PeriodicalId":19252,"journal":{"name":"Neurology, neuropsychiatry, Psychosomatics","volume":"22 4","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-02-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140449588","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Transient ischemic attack in the vertebrobasilar vascular territory as a cause of isolated vertigo","authors":"A. A. Kulesh","doi":"10.14412/2074-2711-2024-1-16-23","DOIUrl":"https://doi.org/10.14412/2074-2711-2024-1-16-23","url":null,"abstract":"Transient ischemic attack (TIA) in the vertebrobasilar vascular territory (VB) causes difficulties in diagnosis when it manifests only with vestibular symptoms. Issues relating to the differential diagnosis of TIA are discussed, awareness of which is necessary for the selection of informative methods of examination and the prescription of effective stroke prevention in patients with an episode of isolated dizziness. The likelihood of TIA as the cause of dizziness is increased by the patients' high cardiovascular risk, the presence of atrial fibrillation, severe instability during an attack, and head and/or neck pain. If a TIA in VB is suspected, it is advisable to perform a minimal instrumental examination, including computed tomography (CT) of the brain and CT angiography or diffusion-weighted magnetic resonance imaging (MRI) and MRI angiography. In case of doubt, additional information can be obtained by a perfusion CT or MRI as well as a post-contrast MRI. When interpreting the results of these methods of examination, their limitations in terms of application time and resolution should be taken into account. ","PeriodicalId":19252,"journal":{"name":"Neurology, neuropsychiatry, Psychosomatics","volume":"113 ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-02-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140449232","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Alternative and complementary treatments for migraine","authors":"G. R. Tabeeva, E. Filatova, A. V. Amelin, V. V. Osipova, A. Artemenko, L. R. Akhmadeeva, E. V. Ekusheva, M. Koreshkina, E. Lebedeva, A. Sergeev, V. Golovacheva, N. Latysheva, M. Naprienko, K. Skorobogatykh, Y. Azimova, A. P. Rachin, V. A. Parfenov","doi":"10.14412/2074-2711-2024-1-4-15","DOIUrl":"https://doi.org/10.14412/2074-2711-2024-1-4-15","url":null,"abstract":"Migraine is a chronic neurological disorder that is associated with considerable disadaptive effect on patients. Despite the development of pharmacotherapy strategies for migraine, only one third of patients are satisfied with their overall treatment. Many migraine patients turn to complementary and alternative medicine (CAM), which is not usually considered a part of conventional medicine and is not always evidence-based. In practise, however, they are often used to improve the effectiveness of standard therapy or to provide alternative treatment. In addition, in CAM methods, the patient is actively involved in the choice of treatment strategies, and they have good adherence. The basic principles and approaches of CAM are increasingly being introduced into clinical practise. This review discusses the principles of CAM in the treatment of migraine as a holistic approach using lifestyle strategies and selected non-pharmacological treatments that have been shown to be effective and rational.","PeriodicalId":19252,"journal":{"name":"Neurology, neuropsychiatry, Psychosomatics","volume":"288 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-02-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140453950","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Ofatumumab – the first fully human monoclonal antibody approved for the treatment of multiple sclerosis","authors":"E. V. Popova","doi":"10.14412/2074-2711-2023-6-142-145","DOIUrl":"https://doi.org/10.14412/2074-2711-2023-6-142-145","url":null,"abstract":"Currently, more than 15 molecules are already approved for the treatment of multiple sclerosis, and sometimes physicians encounter problems selecting a drug for therapy when considering patients with the initial equivalent characteristics. When selecting a drug, it is important to consider not only the efficacy and safety of the drug, but also the possibility of further therapy after discontinuation of the initially selected drug. This paper discusses the results of clinical trials on the efficacy and safety of ofatumumab and its potential advantages over other anti-CD20 agents.","PeriodicalId":19252,"journal":{"name":"Neurology, neuropsychiatry, Psychosomatics","volume":"24 17","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-12-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138965750","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Neurohumoral gate for the entry of coronavirus into the central nervous system through the cribriform plate of the skull","authors":"V. N. Nikolenko, M. Oganesyan, N. Rizaeva, A. T. Nikitina, M. Pavliv, А. V. Polyakova, E. A. Sozonova, M. Khabibov","doi":"10.14412/2074-2711-2023-6-115-121","DOIUrl":"https://doi.org/10.14412/2074-2711-2023-6-115-121","url":null,"abstract":"Recent research has shown that there are different drainage systems in the brain. During the drainage of cerebrospinal and interstitial fluids, intracerebral (intracranial) lymph is formed, which becomes part of the glymphatic system. Later, the glymphatic system was subdivided into periand paravascular spaces, but their existence has not yet been proven. The article contains data on the anatomy of the lamina cribrosa, its age-related changes, the characteristics of the lymphatic system and the theory of the existence of glymphatic vessels in this area. We also hypothesize that in addition to the classical view, which assumes that viruses enter the central nervous system (CNS) through the blood-brain barrier or with the help of immune cells, there are other routes of pathogen entry, for example through the glymphatic system. Possible routes of movement of cerebrospinal and interstitial fluids through the structures of the nervous system and other systems are considered. The lamina cribrosa is considered a possible portal of entry for viruses into the CNS, in particular for the SARS-CoV-2 virus. In our review, we analyzed the likely mechanisms of SARS-CoV-2 spread in the central nervous system and the possible consequences of previous viral disease.","PeriodicalId":19252,"journal":{"name":"Neurology, neuropsychiatry, Psychosomatics","volume":"8 3","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-12-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138966550","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Choline alfoscerate in the correction of cognitive impairment","authors":"O. A. Shavlovskaya, I. D. Romanov, I. A. Bokova","doi":"10.14412/2074-2711-2023-6-128-134","DOIUrl":"https://doi.org/10.14412/2074-2711-2023-6-128-134","url":null,"abstract":"In preclinical and clinical studies, choline alfoscerate (CA) has proven to be highly effective in the correction of cognitive impairment (CI). The clinical effect of CA is seen in the improvement of mental activity, concentration, ability to remember and recall information, cognitive and behavioural responses, elimination of emotional instability and apathy. Experimental studies have shown the effectiveness of CA in preventing atrophic changes in the cerebral cortex. Based on several studies conducted on the use of CA in the treatment of CI, it can be concluded that oral administration of CA at a dose of 600 mg/day can be recommended both as monotherapy and as part of complex therapy in patients with cerebrovascular diseases such as chronic cerebral ischemia. As part of complex therapy for CI in Alzheimer's disease, a combination of CA at a dose of 1200 mg/day with donepezil at a dose of 10 mg/day may be recommended. Several studies have demonstrated the efficacy of CA in the treatment of post-COVID and post-traumatic CI. The efficacy of CA administration in the treatment of CI (including vascular dementia) following ischemic stroke and transient ischemic attacks has been demonstrated. When CA is taken, there is also a reduction in anxiety and depressive disorders, asthenia, the severity of pain symptoms and changes in coordination. The duration of therapy should be 60 to 90 days, depending on the severity of CI, followed by an observation phase of up to 2 years. For successful treatment with CA, it is necessary to carry out repeated courses of CI treatment. Today, a new drug Cerpechol (600 mg/7 ml) has appeared on the Russian market, which has all the effects of CA. The convenience of the new form (oral solution) makes it possible to use it in patients with swallowing disorders.","PeriodicalId":19252,"journal":{"name":"Neurology, neuropsychiatry, Psychosomatics","volume":"19 2","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-12-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138966158","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A case of chorea with cognitive impairment associated with polycythemia vera","authors":"Yu. A. Shpilyukova, O. Smetanina, A. A. Kolpina, S. N. Illarioshkin","doi":"10.14412/20742711-2023-6-101-108","DOIUrl":"https://doi.org/10.14412/20742711-2023-6-101-108","url":null,"abstract":"Polycythemia vera (PV) is a clonal myeloproliferative disorder that is often associated with neurological symptoms. Rare manifestations of PV may include movement disorders (mainly chorea) and cognitive impairment (CI), which are fully or partially reversible with appropriate treatment. We present a case of chorea with CI in a 69-year-old man with a confirmed с1849G>T (V617F) mutation in the JAK2 gene with no vascular pathology on neuroimaging. In this patient, there is a clear correlation between the regression of the movement disorders with therapeutic phlebotomy and the start of treatment with hydroxyurea, which allows the conclusion that chorea has the secondary form. The cognitive symptoms remained at the same level after the start of treatment and during the one-year follow-up and did not develop further. In view of the patient's age, a concomitant neurodegenerative disease cannot be ruled out. In elderly patients with new-onset chorea and CI, it is therefore important to consider PV as a possible cause of these disorders, as early diagnosis of this condition allows timely initiation of effective treatment and prevention of the development of complications.","PeriodicalId":19252,"journal":{"name":"Neurology, neuropsychiatry, Psychosomatics","volume":"353 14‐15","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-12-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138966615","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}